Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient.

Gopal Basu, Anjali Mohapatra, Marie Therese Manipadam, Sunithi Elizabeth Mani, George Tharayil John

Research output: Contribution to journalArticleOtherpeer-review

15 Citations (Scopus)


Current treatment of Kaposi's sarcoma is reduction of immunosuppression with or without addition of mammalian target of rapamycin inhibitors (mTORi). Akt signalling plays a central role in oncogenesis of Kaposi's sarcoma. We describe a case of multifocal Kaposi's sarcoma in a renal allograft recipient, which showed unsatisfactory early response to immunosuppression reduction along with everolimus therapy but completely resolved after adding leflunomide. mTORi impair Kaposi's sarcoma oncogenesis by inhibiting mTOR downstream from the Akt signalling. Leflunomide inhibits Akt phosphorylation. This synergistic effect may be beneficial in treatment of Kaposi sarcoma and needs to be explored in trials.

Original languageEnglish
Pages (from-to)3412-3415
Number of pages4
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Issue number10
Publication statusPublished - Oct 2011
Externally publishedYes

Cite this